Duration of cytochrome P-450 2E1 (CYP2E1) inhibition and estimation of functional CYP2E1 enzyme half-life after single-dose disulfiram administration in humans

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 1, 1999, Pages 213-219

  Emery, Maurice G ^a   Jubert, Carole ^a   Thummel, Kenneth E ^a   Kharasch, Evan D ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MERCAPTOTHIOPROLINE; CHLORZOXAZONE; CYTOCHROME P450; DIMETHYLNITROSAMINE DEMETHYLASE; DISULFIRAM; UNCLASSIFIED DRUG;

ARTICLE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MECHANISM; ENZYME INHIBITION; ENZYME KINETICS; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; XENOBIOTIC METABOLISM;

CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; DISULFIRAM; ENZYME INHIBITORS; FEMALE; HALF-LIFE; HUMANS; MALE; SUBSTRATE SPECIFICITY; TIME FACTORS;

EID: 0032849028     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Brady JF, Xiao F, Wang M-H, Li Y, Ning SM, Gapac JM and Yang CS (1991) Effects of disulfiram on hepatic P450IIE1, other microsomal enzymes and hepatotoxicity in rate. Toxicol Appl Pharmacol 108:366-373.
2. Chen L, Mohr SN and Yang CS (1996) Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of watercress by human volunteers. Clin Pharmacol Ther 80:651-660.
3. Chien JY, Peter RM, Nolan CM, Wartell C, Slattery JT, Nelson SD, Carithers J, RL and Thummel KE (1997b) Influence of polymorphic N-acetyltransferase phenotype on the inhibition and induction of acetaminophen bioactivation with long-term isoniazid. Clin Pharmacol Ther 61:24-34.
4. Chien JY, Thummel KE and Slattery JT (1997a) Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization. Drug Metab Dispos 25:1165-1174.
5. Cobby J, Mayersohn M and Selliah S (1977) The rapid reduction of disulfiram in blood and plasma. J Pharmacol Exp Ther 202:724-731.
6. Eap CB, Schnyder C, Besson J, Savary L and Buclin T (1998) Inhibition of CYP2E1 by chlormethiazole as measured by chlorzoxazone pharmacokinetics in patients with alcoholism and in healthy volunteers. Clin Pharmacol Ther 64:52-57.
7. Eckes L and Buch HP (1985) Influence of disulfiram, diethyldithiocarbamate and carbon disulfide on the metabolic formation of trifluoroacetic acid from halothane in the rat. Arzneimittelforschung 35:1447-1451.
8. Eneanya DI, Bianchine JR, Duran DO and Andresen BD (1981) The actions and metabolic fate of disulfiram. Annu Rev Pharmacol Toxicol 21:575-596.
9. Engel G, Hofmann U, Heidemann H, Cosme J and Eichelbaum M (1996) Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P460 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 59:613-623.
10. Faiman MD, Jensen JC and Lacoursiere RB (1984) Elimination kinetics of disulfiram in alcoholics after single and repeated doses. Clin Pharmacol Ther 36:520-526.
11. Gebhardt AC, Lucas D, Ménez J-F and Seitz HK (1997) Chlormethiazole inhibition of cytochrome P450 2E1 as assessed by chlorzoxazone hydroxylation in humans. Hepatology 26:957-961.
12. Girre C, Lucas D, Hispard E, Menez C, Dally S and Menez J-F (1994) Assessment of cytochrome P4502E1 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 47:1503-1508.
13. Guengerich FP and Shimada T (1991) Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4:391-407.
14. Hu P, Jin L and Baillie TA (1997) Studies on the metabolic activation of disulfiram in rat. Evidence for electrophilic S-oxygenated metabolites as inhibitors of aldehyde dehydrogenase and precursors of urinary N-acetylcysteine conjugates. J Pharmacol Exp Ther 281:611-617.
15. Hu Y, Mishin V, Johansson I, von Bahr C, Cross A, Ronis MJJ, Badger TM and Ingelman-Sundberg M (1994) Chlormethiazole as an efficient inhibitor of cytochrome P450 2E1 expression in rat liver. J Pharmacol Exp Ther 269:1286-1291.
16. Johansson B (1985) Bis-(-diethyldithiocarbamate) copper complex: A new metabolite of disulfiram. Biochem Pharmacol 34:2989-2991.
17. Johansson B (1992) A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl 369:15-26.
18. 2 by dithiocarbamates. Chem Res Toxicol 9:910-916.
19. Kharasch ED, Armstrong AS, Gunn K, Artru A and Cox K (1995) Clinical sevoflurane metabolism and disposition: II. The role of cytochrome P450 2E1 in fluoride and hexafluoroisopropanol formation. Anesthesiology 82:1379-1388.
20. Kharasch ED, Hankins DC, Baxter PJ and Thummel KE (1998) Single-dose disulfiram does not inhibit CYP2A6 activity. Clin Pharmacol Ther 64:39-45.
21. Kharasch ED, Hankins DC and Cox K (1999a) Clinical isoflurane metabolism by cytochrome P450 2E1. Anesthesiology 90:766-771.
22. Kharasch ED, Hankins DC, Jubert C, Thummel KE and Taraday JK (1999b) Lack of single-dose disulfiram effects on cytochrome P450 2C9, 2C19, 2D6 and 3A4 activities. Evidence for specificity towards P450 2E1. Drug Metab Dispos 27:717-723.
23. Kharasch ED, Hankins D, Mautz D, Thummel KE (1996) Identification of the enzyme responsible for oxidative halothane metabolism: Implications for prevention of halothane hepatitis. Lancet 347:1367-1371.
24. Kharasch ED, Thummel KE, Mautz D and Bosse S (1994) Clinical enflurane metabolism by cytochrome P450 2E1. Clin Pharmacol Ther 55:434-440.
25. Kharasch ED, Thummel KE, Mhyre J and Lillibridge JH (1993) Single-dose disulfiram inhibition of chlorzoxazone metabolism: A clinical probe for P450 2E1. Clin Pharmacol Ther 53:643-650.
26. 2 to TTCA in rats. Arch Toxicol 69:185-190.
27. Lam JP, Mays DC and Lipsky JJ (1997) Inhibition of recombinant human mitochondrial and cytosolic aldehyde dehydrogenases by two candidates for the active metabolites of disulfiram. Biochemistry 36:13748-13754.
28. Leclercq I, Desager J-P and Horsmans Y (1998) Inhibition of chlorzoxazone metabolism, a clinical probe for CYP2E1, by a single ingestion of watercress. Clin Pharmacol Ther 64:144-149.
29. Levy RH, Lai AA and Dumain MS (1979) Time-dependent kinetics IV: Pharmacokinetic theory of enzyme induction. J Pharm Sci 68:398-399.
30. Lucas D, Menez C, Girre C, Bodenez P, Hispard E and Menez JF (1995) Decrease in cytochrome P4502E1 as assessed by the rate of chlorzoxazone hydroxylation in alcoholics during the withdrawal phase. Alcohol Clin Exp Res 19:362-366.
31. Mays DC, Ortiz-Bermudez P, Lam JP, Tong IH, Fauq AH and Lipsky JJ (1998) Inhibition of recombinant human mitochondrial aldehyde dehydrogenase by two intermediate metabolites of disulfiram. Biochem Pharmacol 55:1099-1103.
32. McCarver DG, Byun R, Hines RN, Hichme M and Wegenek W (1998) A genetic polymorphism in the regulatory sequences of human CYP2E1: Association with increased chlorzoxazone hydroxylation in the presence of obesity and ethanol intake. Toxicol Appl Pharmacol 152:276-281.
33. Mitra AK, Thummel KE, Kalhorn TF, Kharasch ED, Unadkat JD and Slattery JT (1995) Metabolism of dapsone to its hydroxylamine by CYP2E1 in vitro and in vivo. Clin Pharmacol Ther 58:556-566.
34. Mönig H, Back DJ, Heidemann HT, Ohnhaus EE, Brockmann B and Schulte HM (1993) Effect of chlormethiazole on hepatic monooxygenases activity in vivo. Eur J Clin Pharmacol 44:203-204.
35. m aldehyde dehydrogenase inhibition and implications for its alcohol-deterrent action. Biochem Pharmacol 55:749-756.
36. O'Shea D, Kim RB and Wilkinson GR (1997) Modulation of CYP2E1 activity by isoniazid in rapid and slow N-acetylators. Br J Clin Pharmacol 43:99-103.
37. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP and Yang CS (1990) Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 3:566-573.
38. Roberts BJ, Song BJ, Soh Y, Park SS and Shoaf SE (1995) Ethanol induces CYP2E1 by protein stabilization. Role of ubiquitin conjugation in the rapid degradation of CYP2E1. J Biol Chem 270:29632-29635.
39. Rosier J, Veulemans H, Masschelein R, Vanhoorne M and Van Peteghem C (1987) Experimental human exposure to carbon disulfide. II. Urinary excretion of 2-thiothiazolidine-4-carboxylic acid (TTCA) during and after exposure. Int Arch Occup Environ Health 59:243-250.
40. Sharer JE and Wrighton SA (1996) Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos 24:487-494.
41. Shimada T, Yamazaki H, Mimura M, Inui Y and Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
42. Simon P, Nicot T and Dieudonne M (1994) Dietary habits, a non-negligible source of 2-thiothiazolidine-4-carboxylic acid and possible overestimation of carbon disulfide exposure. Int Arch Occup Environ Health 66:85-90.
43. Song BJ, Veech RL, Park SS, Gelboin HV and Gonzalez FJ (1989) Induction of rat hepatic N-nitrosodimethylamine demethylase by acetone is due to protein stabilization. J Biol Chem 264:3568-3572.
44. Song BJ (1996) Ethanol-inducible cytochrome P450 (CYP2E1): Biochemistry, molecular biology and clinical relevance: 1996 update. Alcohol Clin Exp Res 20 (Suppl): 138A-146A.
45. Thummel KE, Kharasch ED, Podoll T and Kunze K (1993) Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab Dispos 21:350-357.
46. Tsutsumi M, Lasker JM, Takahashi T and Lieber CS (1993) In vivo induction of hepatic P4502E1 by ethanol: Role of increased enzyme synthesis. Arch Biochem Biophys 304:209-218.
47. van Doom R, Leijdekkers CM, Nossent SM and Henderson PT (1982) Excretion of TTCA in human urine after administration of disulfiram. Toxicol Lett 12:59-64.
48. Zand R, Nelson SD, Slattery JT, Thummel KE, Kalhorn TF, Adams SP and Wright JM (1993) Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 54:142-149.